Genotype and allele frequencies of C3435T polymorphism of the MDR1 gene in various jewish populations of Israel

Therapeutic Drug Monitoring

Volumn 26, Issue 6, 2004, Pages 679-684

  Ostrovsky, Olga ^a   Nagler, Arnon ^a   Korostishevsky, Michael ^b   Gazit, Ephraim ^a   Galski, Hanan ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

C3435t polymorphism; Ethnicity; MDR1 gene; P glycoprotein; Populations

Indexed keywords

GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; AFRICA; ARTICLE; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; ISRAEL; JEW; MALE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POPULATION GENETICS; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADOLESCENT; ADULT; ALLELES; CYTOSINE; FEMALE; GENE FREQUENCY; GENES, MDR; GENOTYPE; HUMANS; ISRAEL; JEWS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; THYMINE;

EID: 9644263928     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200412000-00015     Document Type: Article

References (39)

1. Lehne G. P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. Curr Drug Targets. 2000;1:85-99.
2. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, et al. P-glycoprotein: from genomics to mechanism. Oncogene. 2003;22:7468-7485.
3. Goldstein LJ, Galski H, Fojo A, et al. Expression of a multidrug resistance gene in human cancer. J Natl Cancer Inst. 1989;81:116-124.
4. Galski H, Sullivan M, Willingham MC, et al. Expression of a human multidrug resistance cDNA (MDR1) in the bone marrow of transgenic mice: resistance to daunomycin-induced leukopenia. Mol Cell Biol. 1989;9:4357-4363.
5. Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol. 2003;43: 285-307.
6. Fromm MF. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev. 2002;54:1295-1310.
7. Zheng HX, Webber S, Zeevi A, et al. The MDR1 polymorphisms at exon 21 and 26 predict steroid weaning in pediatric heart transplant patients. Hum Immunol. 2002;63:765-770.
8. Marzolini C, Paus E, Buclin T, et al. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004;75:13-33.
9. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 2000;97:3473-3478.
10. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetic study. Lancet. 2002;359:30-36.
11. Tanabe M, Ieiri I, Nagata N, et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther. 2001;297:1137-1143.
12. - natural killer cells. Pharmacogenetics. 2001;11:293-298.
13. Sakaeda T, Kakamura T, Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics. 2003;4:397-410.
14. Dietrich CG, Geier A, Matern S, et al. Multidrug resistance and response to antiretroviral treatment. Lancet. 2002;359:2114.
15. Illmer T, Schuler US, Thiede C, et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res. 2002;62:4955-4962.
16. Stanulla M, Schaeffeler E, Schrappe M, et al. An association between the MDR1 C3435T polymorphism and CNS relapse in childhood ALL. Eur J Clin Pharmacol. 2001;57:A28.
17. Furuno T, Landi MT, Ceroni M, et al. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics. 2002;12:529-534.
18. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol. 1998;161:5733-5744.
19. Atanasova S, von Ahsen N, Dimitrov T, et al. MDR1 haplotypes modify BEN disease risk: a study in Bulgarian patients with Balkan endemic nephropathy compared to healthy controls. Nephron Exp Nephrol. 2004;96:e7-13.
20. Ameyaw MM, Regateiro F, Li T, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics. 2001; 11:217-221.
21. Cavaco I, Gill JP, Gil-Berglund E, et al. CYP3A4 and MDR1 alleles in a Portuguese population. Clin Chem Lab Med. 2003;41:1345-1350.
22. Balram C, Sharma A, Sivathasan C, et al. Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates. Br J Clin Pharmacol. 2003;56:78-83.
23. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001;70:189-199.
24. Cascorbi T, Gerloff A, Johne C, et al. Frequency of single nucleotide polymorphisms (SNPs) in the P-glycoprotein drug transporter MDR1 gene in Caucasians. Clin Pharmacol Ther. 2001;69:169-174.
25. Bernal ML, Sinues B, Fanlo A, et al. Frequency distribution of C3435T mutation in exon 26 of the MDR1 gene in a Spanish population. Ther Drug Monit. 2003;25:107-111.
26. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol. 2003;59:303-312.
27. Schneider S, Roessli D, Excoffer L. A software for population genetic data analysis. Manual Arlequin, version 2.00. Geneva: University of Geneva, 2000.
28. Guo S, Thomson E. Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics. 1992;48:361-372.
29. Nei M, Li WH. Mathematical model for studying genetic variation in terms of restriction endonucleases. Proc Natl Acad Sci USA. 1979;76: 5269-5273.
30. Raymond M, Rousset F. An exact test for population differentiation. Evolution. 1995;49:1280-1283.
31. Hammer MF, Redd AJ, Wood ET, et al. Jewish and Middle Eastern non-Jewish populations share a common pool of Y-chromosome biallelic haplotypes. Proc Natl Acad Sci USA. 2000;97:6769-6774.
32. Kobyliansky E, Micle S, Goldschmidt-Nathan M, et al. Jewish populations of the world: genetic likeness and differences. Ann Hum Biol. 1982;9:1-34.
33. Deitrich CG, Geier A, Oude Elferink RPJ. ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut. 2003;52:1788-1795.
34. Schaeffeler E, Eichelbaum M, Brinkmann U, et al. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet. 2001;358:383-384.
35. Tang K, Wong LP, Lee EJD, et al. Genomic evidence for recent positive selection at the humanMDR1 gene locus. Hum Mol Genet. 2004;13:783-797.
36. Kimchi-Sarfaty C, Gribar JJ, Gottesman MM. Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol Pharm. 2002;62:1-6.
37. Schwab M, Schaeffeler E, Marx C, et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology. 2003;124:26-33.
38. Johne A, Kopke K, Gerloff T, et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther. 2002;72:584-594.
39. Kurata Y, Ieiri I, Kimura M, et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther. 2002;72:209-219.